The peroxisome proliferator-activated receptor Á (PPARÁ) has been suggested to act as a tumor suppressor gene. Two common variations of PPARÁ, P12A (Pro12Ala, rs1801282) and C161T (His447His, rs3856806), are thought to have an effect on susceptibility to various carcinomas but the results are inconsistent. In this meta-analysis, we assessed published studies of the association between two common PPARÁ polymorphisms and cancer risk from 26 studies with 27,677 subjects for PPARÁ P12A, from 4 studies with 4,461 subjects for C161T. No significant associations were found in carriers of the rare Ala allele of the P12A polymorphism versus the common Pro/Pro genotype among the studies. In the subgroup analyses by cancer types, carriers of the Ala variant of P12A polymorphism were associated with protection from colorectal cancer (OR=0.84, 95% CI=0.72-0.98, P heterogeneity = 0.014), but the inverse association was found in gastric cancer (OR=2.31, 95% CI=1.59-3.36, P heterogeneity = 0.941). In the stratified analysis by ethnicity, no significant risks were found among Asians, Americans and Caucasians. For PPARÁ C161T, no significant associations were found in any of the studies (OR=1.08, 95% CI=0.95-1.23, P heterogeneity = 0.430) or subgroups. This meta-analysis suggests that the Ala allele of the PPARÁ P12A polymorphism might be a protective factor for colorectal cancer, but a risk factor for gastric cancer. The PPARÁ C161T is marginally associated with cancer susceptibility.
Introduction
Over the past decade, strides have been made in treating several solid tumor malignancies resulting in measurable increases in survival, but cancer is projected to become the leading cause of death worldwide in 2010 and a great challenge remains to establish improved cancer prevention and treatment strategies for most cancers. The world urgently needs safe and effective drugs against cancer. The potential of peroxisome proliferator-activated receptor Á (PPARÁ) as a useful target for the prevention and treatment of cancer has been widely studied. In addition to the known roles in regulation of metabolism and inflammation, mounting evidence shows once activated PPARÁ will down-regulate carcinogenesis by preferentially binding with retinoid X receptor · (RXR), and signaling antiproliferative, antiangiogenic, and prodifferentiation pathways (1) .
PPARs are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. Of the three PPAR isoforms identified to date (PPAR·, PPARß, and PPARÁ), PPARÁ has been the most intensively studied in part because of the availability of PPARÁ agonists (2) . The PPARÁ gene at chromosome 3p25 (OMIM *601487) in humans appears to be a suitable candidate gene for cancer susceptibility through its pleiotropic activity (3) . Two PPARÁ common polymorphisms, a C➝G transition in exon B resulting in a proline to alanine exchange at amino acid position 12 (P12A) (OMIM *0002; rs1801282) and a C➝T transition at position 161 in exon 6 (C161T) (OMIM *0009; rs3856806) have been identified and found to be associated with the risk of type 2 diabetes and cardiovascular events (4, 5) . In recent years evidence shows that both variations may also influence individual susceptibility to several types of cancer, such as those that occur in the central nervous system (6) , lung (7, 8) , stomach (9) (10) (11) (12) , biliary tract (13) , colorectum (14) (15) (16) (17) (18) (19) (20) (21) (22) , bladder (23) , breast (24) (25) (26) (27) , ovaries (28) , endometrium (29) , prostate (30) (31) (32) , kidney (28) and skin (33) . However, the observed results of these studies were inconsistent. We performed a meta-analysis to derive a more precise estimation of the association of PPARÁ polymorphisms with cancer risk. polymorphism' and 'carcinoma' (last search was updated on January 1, 2010). The search was done without restriction on the language but was focused on the studies that had been conducted on human subjects. We also reviewed the Cochrane Library for relevant articles. The reference lists of reviews and retrieved articles were hand searched simultaneously. Only published studies with full text articles were included. When more than one of the same patient population was included in several publications, only the most recent study was used in this meta-analysis. Studies included in the current meta-analysis had to meet all the following criteria: a) evaluation of the PPARÁ polymorphisms and cancer risk, b) malignant tumors were histologically confirmed and c) sufficient published data for estimating an odds ratio (OR) with 95% confidence interval (CI).
Data extraction. Data were independently abstracted in duplicate by two investigators using a standard protocol and data-collection form according to the inclusion criteria listed above. Disagreement was resolved by discussion between the two authors. Characteristics abstracted from the studies included the first author's surname, publication date, country origin, ethnicity, tumor type, characteristics of controls, genotyping methods, total number of cases and controls, and numbers of genotypes, respectively. Different racial descents were categorized as Asians, Caucasians and Americans. When studies included subjects of more than one ethnicity and they could be separated, data were extracted separately for each ethnic group.
Statistical methods. OR corresponding to 95% CI was used to assess the strength of association between PPARÁ polymorphism and cancer. For PPARÁ P12A, the meta-analysis examined the association between the carriers of the rare Ala allele and cancer risk compared with that for Pro/Pro genetype (CG+GG vs. CC). For the C161T, the association between carriers of T variant and CC genetype (CT+TT vs. CC) with cancer risk was also examined. Subgroup analyses were done by ethnicity and tumor type. Heterogeneity assumption was checked by the Chi-square-based Q-test (34) . P>0.10 for the Q-test indicates a lack of heterogeneity among the studies, then the pooled OR estimate of each study was calculated by the fixed-effects model (the Mantel-Haenszel method) (35) . Otherwise, the random-effects model (the DerSimonian and Laird method) (36) was used. Hardy-Weinberg equilibrium (HWE) was assessed via Fisher's exact test and P<0.05 was considered significant. An estimate of potential publication bias was carried out by the funnel plot and an asymmetric plot suggests a possible publication bias. Funnel plot asymmetry was assessed by the method of Egger's linear regression test. The significance of the intercept was determined by the t-test suggested by Egger et al (P<0.05 was considered representative of statistically significant publication bias) (37) . The statistical analyses were performed with STATA 8.0. (StataCorp, College Station, TX), using two-sided P-values.
Results
Study characteristics and meta-analysis results. There were 32 eligible studies as a result of the search and screening. Of these studies, four (38) (39) (40) (41) were excluded because they did not provide allele frequencies needed for OR calculation or they were studies about benign adenoma or other PPAR subtypes. One study (22) was also excluded because the same data were available in another study. Thus, a total of 26 studies (6-12,14-21,23-33) involving 11,627 cases and 16,050 controls were ultimately analyzed for P12A, five studies (13-16,33) involving 1,819 cases and 2,642 controls for C161T. Five studies (6, 15, 17, 28, 33) sorted the data in different race or different tumor types, therefore, each group in these studies was considered separately for pooling subgroup analyses. Table I presents the main characteristics of these studies. Among 26 publications, 24 were published in English, and two (8, 12) were in Chinese. There were 11 Asians groups (8, (10) (11) (12) (14) (15) (16) 19, 28, 33) , 13 Caucasian groups (6, 7, 9, 13, 18, 21, 23, 24, 27, 28, 33) , and 13 American groups (6, 17, 20, 25, 26, 28, 29, (30) (31) (32) . HWE had been tested in most controls, and most of the controls were in HWE, there were five studies (17, 19, 23, 29, 32) without genotype distribution in detail. Table II listed the main results of this meta-analysis. For PPARÁ P12A, the contrast of CG+GG vs. CC did not produce significant association among 26 studies with relatively large heterogeneity (OR=0.98, 95% CI=0.89-1.09, P heterogeneity = 0.003). Through stratified analyses, the heterogeneity of the subgroup significantly reduced. In the stratified analysis by ethnicity ( Fig. 1 ), no significant risks were found among Asians, Americans and Caucasians. In the subgroup analyses by cancer types, carriers of the Ala variant of P12A polymorphism were associated with protection from colorectal cancer (OR=0.84, 95% CI=0.72-0.98, P heterogeneity = 0.014), but with an increased risk of gastric cancer (OR=2.31, 95% CI=1.59-3.36, P heterogeneity = 0.941). No significant associations were found in breast cancer, prostate carcinoma, oophoroma, bladder cancer, endometrial carcinoma, lung cancer and others in the pooling analyses. For C161T, no significant risks were found in any of the studies (OR=1.08, 95% CI=0.95-1.23, P heterogeneity = 0.430) or subgroups.
Bias diagnostics. Begg's funnel plot and Egger's test were performed to access the publication bias of the literatures. The funnel plots for publication bias showed some asymmetry (Fig.2 ), but Egger's test suggested that there was no publication bias in the current meta-analysis (for P12A, P=0.493 and for C161T, P=0.742).
Discussion
PPARÁ is manifested in a variety of cancer cells. Upon ligand binding, the PPAR/RXR heterodimer associates with coactivator complexes, binds peroxisome proliferator response elements (PPREs), and activates the transcription of PPARresponsive genes (42) , which generally reduces the survival ONCOLOGY REPORTS 24: 579-585, 2010 Table I . Characteristics of the studies investigated for association between PPAR polymorphisms.
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rate of cancer cells through induction of cell cycle arrest and apoptosis. Synthetic ligands for PPARÁ are currently being studied as a possible novel therapeutic modality for certain types of cancer (43) . The most prevalent human PPARÁ gene mutation, Pro12Ala polymorphism, has been extensive investigated. In 1998, Deeb et al reported that a Pro12Ala substitution in PPARÁ associated with reduced transactivation activity (44) . Activation of PPARÁ can affect tumors by inhibiting the expression of key prostanoid and integrin receptors, by reducing the expression of fibronectin, a matrix glycoprotein that stimulates tumor cell proliferation, and by inhibiting the production of angiogenic and inflammatory signals. In addition, PPARÁ ligands can increase the expression and/or activity of tumor suppressors such as PTEN and p21 (45) . Treatment with troglitazone was found to reduce gastric cancer formation in mice induced by carcinogens, and the chemopreventive effect of troglitazone was absent in PPARÁ heterozygous-deficient mice (46) . In the current meta-analysis, we found that patients with G carriers had 2.31-fold (95% CI = 1.59-3.36, P heterogeneity = 0.941) increased risk of gastric cancer, suggesting the presence of the Ala12 polymorphism, which is associated with reduced PPARÁ activity, might increase the susceptibility of gastric cancer.
According to different cancer types, the inverse association was found in colorectal cancer. The apparent discrepancy results may be partly explained by the complex aetiological link between type 2 diabetes and colorectal cancer. There is convincing evidence across diverse populations that obesity and type 2 diabetes elevate the risk of colorectal cancer, which is related to chronic hyperinsulinaemia and hyperglycaemia (47) . In particular, hyperinsulinemic state exhibits procarcinogenic effects in animal models and is believed to be the mechanism that underlies the association between diabetes and colorectal carcinogenesis. The Ala12 was recognized to be associated with increased tissue sensitivity to insulin, a decrease in insulin plasma level, reduced release of free fatty acids by adipocytes (44) , which may indirectly explain the lower risk of colorectal cancer in subjects with this polymorphism. On the contrary, a similar association between ONCOLOGY REPORTS 24: 579-585, 2010 583   Table II . The main results of ORs (95% CI) in the meta-analysis.
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insulin sensitivity or diabetes and gastric cancer is lacking. This also shows different carcinogenic mechanisms of different cancers.
There are only 4 studies involving 1,819 cases and 2,642 controls for C161T polymorphism in the PPARÁ gene and cancer susceptibility. Although a C to T substitution at nucleotide 1431 in exon 6 is a synonymous polymorphism that encodes histidine with either allele, biological relevance is suggested by the results of epidemiological studies showing an association of this polymorphism with metabolic diseases such as type 2 diabetes and atherosclerosis (48) . It is proposed that this substitution may modulate expression of PPARÁ by altering mRNA processing or translation, however, no significant associations were found for this polymorphism with cancer risk in this meta-analysis. Due to limited statistical power, further evaluations are warranted to confirm these results.
Caution must be taken in the interpretation of the results because of the relatively large heterogeneity in all studies. In the subgroup analyses stratified by tumor site and racial descent respectively, it can be found that the heterogeneity of the subgroup reduced significantly. Therefore, it can be presumed that the relatively large heterogeneity mainly results from differences of ethnicity and tumor types. Simultaneously, the heterogeneity may also have been caused by the differences in the selection of controls, age distribution and lifestyle factors. Publication bias may exist, because only published studies were included in this meta-analysis, and non-significant or negative findings may remain unpublished. Finally, current results were based on unadjusted estimates, while a more precise analysis should be conducted if individual data were available.
In conclusion, this meta-analysis suggests that the PPARÁ P12A polymorphism most likely contributes to decreased susceptibility to colorectal cancer, but Ala12 allele may be a risk factor for gastric cancer. PPARÁ C161T polymorphism is marginally associated with cancer susceptibility. Due to the limitations of the current meta-analysis, larger association studies or multicentric studies and studies assessing geneenvironment and gene-gene interaction are warranted to confirm these findings.
